Psoriasis clinical trials
35 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
- Duobrii in Combination With Biologics
- An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients
- Multi-Center PAMPA Study
- Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors
- Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
- Taltz in Combination With Enstilar for Psoriasis
- Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
- A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- PPD™ CorEvitas™ Psoriasis (PSO) Early Treatment Response Non-Interventional Study
- A Study to Assess Deucravacitinib Safety in Pregnancy
- Regulation of Inflammatory Genes in Psoriasis
- Metabolic Profiling of Immune Responses in Immune-mediated Diseases
- Skin Microbial Ecology in Atopic Dermatitis
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
- IMPACT - AndHealth Autoimmune Research Registry
- Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
- Characterization of the Microbiome in Cutaneous T Cell Lymphoma
- Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- The Effects of Audio-Based Therapy on Anxiety in Psoriasis
- Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
- A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis
- Immune Spatial Features of Guselkumab Cutaneous Response
- The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease
- A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
- Assessing Psoriasis Treatment Outcomes
- Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)
- LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
- Thera-Clean® Microbubbles System in Patients With Skin Diseases
- Quest to Analyze One Thousand Humans Meditating
- Psoriatic Arthritis D2P Screening
- Psorcast Mobile Study
- Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Psoriasis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.